2019
DOI: 10.1136/ijgc-2019-000499
|View full text |Cite
|
Sign up to set email alerts
|

Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies

Abstract: The use of poly(ADP-ribose) polymerase (PARP) inhibition is transforming care for the treatment of ovarian cancer, with three different PARP inhibitors (PARPi) gaining US Food and Drug Administration approval since 2014. Given the rapidly expanding use of PARPi, this review aims to summarize the key evidence for their use and therapeutic indications. Furthermore, we provide an overview of the development of PARPi resistance and the emerging role of PARPi combination therapies, including those with anti-angioge… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 78 publications
0
1
0
Order By: Relevance
“…The additional use of DNA damaging agents might lead to an increased dependence on PARP1 activity for repair and by this would amplify a cells/tumors sensitivity to PARP inhibition. Combination therapies of PARPi with other DNA damaging therapies such as radiation therapy, chemotherapeutic drugs (e.g., Doxorubicin) [10] or anti-angiogenic therapy and immunotherapy are being assessed to improve cytotoxicity, and by this, the therapy efficacy and outcome as discussed in a recent review [11].…”
Section: Introductionmentioning
confidence: 99%
“…The additional use of DNA damaging agents might lead to an increased dependence on PARP1 activity for repair and by this would amplify a cells/tumors sensitivity to PARP inhibition. Combination therapies of PARPi with other DNA damaging therapies such as radiation therapy, chemotherapeutic drugs (e.g., Doxorubicin) [10] or anti-angiogenic therapy and immunotherapy are being assessed to improve cytotoxicity, and by this, the therapy efficacy and outcome as discussed in a recent review [11].…”
Section: Introductionmentioning
confidence: 99%